On this page
Alclometasone dipropionate
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Alclometasone Dipropionate | .5 mg/g | 855474 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 076730-001 | ALCLOMETASONE DIPROPIONATE | OINTMENT | ALCLOMETASONE DIPROPIONATE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 7 | Labeling | Approved | July 26, 2011 | — |
| Original application | 1 | Approved | July 29, 2004 | — |
Review documents
- 0 · Original application · July 30, 2004
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20210405). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Alclometasone dipropionate cream and ointment are low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Alclometasone dipropionate cream and ointment may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see PRECAUTIONS: Pediatric Use ). Since the safety and efficacy of alclometasone dipropionate cream and ointment have not been established in pediatric patients below 1 year of age, their use in this age-group is not recommended.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply a thin film of alclometasone dipropionate cream or ointment to the affected skin areas 2 or 3 times daily; massage gently until the medication disappears. Alclometasone dipropionate cream and ointment may be used in pediatric patients 1 year of age or older. Safety and effectiveness of alclometasone dipropionate cream or ointment in pediatric patients for more than 3 weeks of use have not been established. Use in pediatric patients under 1 year of age is not recommended. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Alclometasone dipropionate cream or ointment should not be used with occlusive dressings unless directed by a physician. Alclometasone dipropionate cream or ointment should not be applied in the diaper area if the child still requires diapers or plastic pants as these garments may constitute occlusive dressing. Geriatric Use : In studies where geriatric patients (65 years of age or older, see PRECAUTIONS ) have been treated with alclometasone dipropionate cream or ointment, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Alclometasone dipropionate cream and ointment are contraindicated in those patients with a history of hypersensitivity to any of the components in these preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions have been reported with alclometasone dipropionate cream in approximately 2% of patients: itching and burning, erythema, dryness, irritation, and papular rashes. The following local adverse reactions have been reported with alclometasone dipropionate ointment in approximately 1% of patients: itching, burning, and erythema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Description
openFDA Drug LabelingDESCRIPTION Alclometasone Dipropionate Cream USP, 0.05% and Alclometasone Dipropionate Ointment USP, 0.05% contain alclometasone dipropionate, USP (7α-chloro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate), a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, alclometasone dipropionate, USP is C 28 H 37 ClO 7 . It has the following structural formula: Alclometasone dipropionate, USP has the molecular weight of 521.04 g/mol. It is a white to almost white crystalline powder, sparingly soluble in alcohol, acetone, ethyl acetate and acetonitrile. Each gram of Alclometasone Dipropionate Cream USP contains 0.5 mg of alclometasone dipropionate, USP in a hydrophilic, emollient cream base of propylene glycol, white petrolatum, cetearyl alcohol, mono and di-glycerides, PEG 100 stearate, ceteth-20, monobasic sodium phosphate, chlorocresol, phosphoric acid, and purified water. Each gram of Alclometasone Dipropionate Ointment USP contains 0.5 mg of alclometasone dipropionate, USP in an ointment base of hexylene glycol, white wax, propylene glycol monopalmitostearate, and white petrolatum. structure-formula
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied alclometasone dipropionate cream and ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Alclometasone Dipropionate Cream USP, 0.05% is supplied in: 15 gram tubes (NDC 68462-300-17) 45 gram tubes (NDC 68462-300-47) 60 gram tubes (NDC 68462-300-65) Alclometasone Dipropionate Ointment USP, 0.05% is supplied in: 15 gram tubes (NDC 68462-299-17) 45 gram tubes (NDC 68462-299-47) 60 gram tubes (NDC 68462-299-65) Store between 2°C and 30°C (36°F and 86°F).
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ALCLOMETASONE DIPROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 68462-299-17 | 68462-299 | Glenmark Pharmaceuticals Inc., USA | 15 g in 1 TUBE (68462-299-17) | July 30, 2009 |
| 68462-299-47 | 68462-299 | Glenmark Pharmaceuticals Inc., USA | 45 g in 1 TUBE (68462-299-47) | July 30, 2009 |
| 68462-299-65 | 68462-299 | Glenmark Pharmaceuticals Inc., USA | 60 g in 1 TUBE (68462-299-65) | July 30, 2009 |
| 51672-1316-1 | 51672-1316 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1316-1) / 15 g in 1 TUBE | July 29, 2004 |
| 51672-1316-3 | 51672-1316 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1316-3) / 60 g in 1 TUBE | July 29, 2004 |
| 51672-1316-5 | 51672-1316 | Sun Pharmaceutical Industries, Inc. | 5 g in 1 TUBE (51672-1316-5) | July 29, 2004 |
| 51672-1316-6 | 51672-1316 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1316-6) / 45 g in 1 TUBE | July 29, 2004 |
| 68462-299 | 68462-299 | Glenmark Pharmaceuticals Inc., USA | — | July 30, 2009 |
| 51672-1316 | 51672-1316 | Sun Pharmaceutical Industries, Inc. | — | July 29, 2004 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.